Neurogene Inc. (NASDAQ:NGNE) CFO Sells $76,246.94 in Stock

Neurogene Inc. (NASDAQ:NGNE - Get Free Report) CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total transaction of $76,246.94. Following the transaction, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. This trade represents a 5.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Neurogene Stock Down 6.6 %

Shares of NGNE stock traded down $1.01 during trading hours on Friday, reaching $14.23. The stock had a trading volume of 161,827 shares, compared to its average volume of 207,594. Neurogene Inc. has a twelve month low of $13.84 and a twelve month high of $74.49. The firm has a 50-day simple moving average of $17.29 and a 200-day simple moving average of $29.66.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and issued a $55.00 price target on shares of Neurogene in a research report on Monday, November 25th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $60.83.

Remove Ads

Hedge Funds Weigh In On Neurogene

Several large investors have recently bought and sold shares of the stock. Vestal Point Capital LP acquired a new position in Neurogene during the 4th quarter valued at about $1,829,000. Squarepoint Ops LLC grew its stake in shares of Neurogene by 250.0% in the 4th quarter. Squarepoint Ops LLC now owns 17,431 shares of the company's stock worth $398,000 after purchasing an additional 12,451 shares during the last quarter. Two Sigma Investments LP acquired a new position in shares of Neurogene in the 4th quarter worth approximately $472,000. RTW Investments LP grew its stake in shares of Neurogene by 18.9% in the 4th quarter. RTW Investments LP now owns 1,350,256 shares of the company's stock worth $30,867,000 after purchasing an additional 215,000 shares during the last quarter. Finally, Raiffeisen Bank International AG acquired a new position in shares of Neurogene in the 4th quarter worth approximately $356,000. Institutional investors and hedge funds own 52.37% of the company's stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.